How Well Do Routine Molecular Diagnostics Detect Rifampin Heteroresistance in Mycobacterium tuberculosis?

Rifampin heteroresistance—where rifampin-resistant and -susceptible tuberculosis (TB) bacilli coexist—may result in failed standard TB treatment and potential spread of rifampin-resistant strains. The detection of rifampin heteroresistance in routine rapid diagnostic tests (RDTs) allows for patients to receive prompt and effective multidrug-resistant-TB treatment and may improve rifampin-resistant TB control. ABSTRACT Rifampin heteroresistance—where rifampin-resistant and -susceptible tuberculosis (TB) bacilli coexist—may result in failed standard TB treatment and potential spread of rifampin-resistant strains. The detection of rifampin heteroresistance in routine rapid diagnostic tests (RDTs) allows for patients to receive prompt and effective multidrug-resistant-TB treatment and may improve rifampin-resistant TB control. The limit of detection (LOD) of rifampin heteroresistance for phenotypic drug susceptibility testing by the proportion method is 1% and, yet, is insufficiently documented for RDTs. We, therefore, aimed to determine, for the four RDTs (XpertMTB/RIF, XpertMTB/RIF Ultra, GenoTypeMTBDRplusv2.0, and GenoscholarNTM+MDRTBII), the LOD per probe and mutation, validated by CFU counting and targeted deep sequencing (Deeplex-MycTB). We selected one rifampin-susceptible and four rifampin-resistant strains, with mutations D435V, H445D, H445Y, and S450L, respectively, mixed them in various proportions in triplicate, tested them with each RDT, and determined the LODs per mutation type. Deeplex-MycTB revealed concordant proportions of the minority resistant variants in the mixtures. The Deeplex-MycTB-validated LODs ranged from 20% to 80% for XpertMTB/RIF, 20% to 70% for Xpert Ultra, 5% to 10% for GenoTypeMTBDRplusv2.0, and 1% to 10% for GenoscholarNTM+MDRTBII for the different mutations. Deeplex-MycTB, GenoTypeMTBDRplusv2.0, and GenoscholarNTM+MDRTBII provide explicit information on rifampin heteroresistance for the most frequently detected mutations. Classic Xpert and Ultra report rifampin heteroresistance as rifampin resistance, while Ultra may denote rifampin heteroresistance through “mixed patterns” of wild-type and mutant melt probe, melt peak temperatures. Overall, our findings inform end users that the threshold for reporting resistance in the case of rifampin heteroresistance is the highest for Classic Xpert and Ultra to resolve phenotypic and genotypic discordant rifampin-resistant TB results.

[1]  P. de Rijk,et al.  Fluoroquinolone heteroresistance in Mycobacterium tuberculosis: detection by genotypic and phenotypic assays in experimentally mixed populations , 2019, Scientific Reports.

[2]  Nandini Dendukuri,et al.  Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults , 2019, The Cochrane database of systematic reviews.

[3]  R. Warren,et al.  Deciphering Within-Host Microevolution of Mycobacterium tuberculosis through Whole-Genome Sequencing: the Phenotypic Impact and Way Forward , 2019, Microbiology and Molecular Biology Reviews.

[4]  S. Duthoy,et al.  Drug-Resistant Tuberculosis, Lebanon, 2016 – 2017 , 2019, Emerging infectious diseases.

[5]  Jean-Charles Delvenne,et al.  Outbreak of multidrug-resistant tuberculosis in South Africa undetected by WHO-endorsed commercial tests: an observational study. , 2018, The Lancet. Infectious diseases.

[6]  Stefan Niemann,et al.  MTBseq: a comprehensive pipeline for whole genome sequence analysis of Mycobacterium tuberculosis complex isolates , 2018, PeerJ.

[7]  L. Rigouts,et al.  Xpert Ultra Can Unambiguously Identify Specific Rifampin Resistance-Conferring Mutations , 2018, Journal of Clinical Microbiology.

[8]  L. Lynen,et al.  Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs. , 2018, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[9]  T. Clark,et al.  Genome-wide analysis of multi- and extensively drug-resistant Mycobacterium tuberculosis , 2018, Nature Genetics.

[10]  D. Falzon,et al.  Culture and Next-generation sequencing-based drug susceptibility testing unveil high levels of drug-resistant-TB in Djibouti: results from the first national survey , 2017, Scientific Reports.

[11]  D. Engelthaler,et al.  Cryptic Microheteroresistance Explains Mycobacterium tuberculosis Phenotypic Resistance , 2017, American journal of respiratory and critical care medicine.

[12]  D. Engelthaler,et al.  Mycobacterium tuberculosis Subculture Results in Loss of Potentially Clinically Relevant Heteroresistance , 2017, Antimicrobial Agents and Chemotherapy.

[13]  D. Alland,et al.  The New Xpert MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing , 2017, mBio.

[14]  D. Operario,et al.  Correction: Prevalence and extent of heteroresistance by next generation sequencing of multidrug-resistant tuberculosis , 2017, PloS one.

[15]  D. Operario,et al.  Prevalence and extent of heteroresistance by next generation sequencing of multidrug-resistant tuberculosis , 2017, PloS one.

[16]  M. Pai,et al.  Tuberculosis Diagnostics: State of the Art and Future Directions. , 2016, Microbiology spectrum.

[17]  Petter Holme,et al.  Connectivity of diagnostic technologies: improving surveillance and accelerating tuberculosis elimination. , 2016, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[18]  L. Rigouts,et al.  Specific gyrA gene mutations predict poor treatment outcome in MDR-TB , 2015, The Journal of antimicrobial chemotherapy.

[19]  Phelim Bradley,et al.  Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study , 2015, The Lancet. Infectious diseases.

[20]  Francesc Coll,et al.  A robust SNP barcode for typing Mycobacterium tuberculosis complex strains , 2014, Nature Communications.

[21]  J. Klausner,et al.  Mixed Mycobacterium tuberculosis Complex Infections and False-Negative Results for Rifampin Resistance by GeneXpert MTB/RIF Are Associated with Poor Clinical Outcomes , 2014, Journal of Clinical Microbiology.

[22]  T. Sterling,et al.  High Proportion of Heteroresistance in gyrA and gyrB in Fluoroquinolone-Resistant Mycobacterium tuberculosis Clinical Isolates , 2014, Antimicrobial Agents and Chemotherapy.

[23]  D. Havlir,et al.  Evaluation of Two Line Probe Assays for Rapid Detection of Mycobacterium tuberculosis, Tuberculosis (TB) Drug Resistance, and Non-TB Mycobacteria in HIV-Infected Individuals with Suspected TB , 2014, Journal of Clinical Microbiology.

[24]  L. Rigouts,et al.  Rifampin Heteroresistance in Mycobacterium tuberculosis Cultures as Detected by Phenotypic and Genotypic Drug Susceptibility Test Methods , 2013, Journal of Clinical Microbiology.

[25]  L. Rigouts,et al.  Rifampin Resistance Missed in Automated Liquid Culture System for Mycobacterium tuberculosis Isolates with Specific rpoB Mutations , 2013, Journal of Clinical Microbiology.

[26]  N. Mistry,et al.  Drug resistance mutations and heteroresistance detected using the GenoType MTBDRplus assay and their implication for treatment outcomes in patients from Mumbai, India , 2012, BMC Infectious Diseases.

[27]  S. Lawn,et al.  Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. , 2011, Future microbiology.

[28]  L. Rigouts,et al.  Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial. , 2011, JAMA.

[29]  J. Kop,et al.  Evaluation of the Analytical Performance of the Xpert MTB/RIF Assay , 2010, Journal of Clinical Microbiology.

[30]  K. Feldmann,et al.  Mechanisms of heteroresistance to isoniazid and rifampin of Mycobacterium tuberculosis in Tashkent, Uzbekistan , 2008, European Respiratory Journal.

[31]  J. Herrmann,et al.  Evaluation of the Inoculation Procedure Using a 0.25 McFarland Standard for the BD Phoenix Automated Microbiology System , 2007, Journal of Clinical Microbiology.

[32]  F. Portaels,et al.  Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[33]  C. Baker,et al.  Inoculum standardization in antimicrobial susceptibility testing: evaluation of overnight agar cultures and the Rapid Inoculum Standardization System , 1983, Journal of clinical microbiology.

[34]  P. Escalante.  Tuberculosis , 1904, Annals of Internal Medicine.

[35]  F Moussy,et al.  The TDR Tuberculosis Strain Bank: a resource for basic science, tool development and diagnostic services. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[36]  GenoType MTBDRplus.  GenoType MTBDRplus VER 2.0 Molecular Genetic Assay for Identification of the M. tuberculosis Complex and its Resistance to Rifampicin and Isoniazid from Clinical Specimens and Cultivated Samples , 2012 .

[37]  A. Khomenko,et al.  Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. , 1969, Bulletin of the World Health Organization.

[38]  P HAUDUROY,et al.  MYCOBACTERIA: LABORATORY METHODS FOR TESTING DRUG SENSITIVITY AND RESISTANCE. , 1963, Bulletin of the World Health Organization.